- Biotech Patent Pools – Overview
- Panels 2 & 3 – Patent Pool of HIV Therapies – Overview
- Panels 4 & 5 – Patent Pool for Neglected Diseases – Overview
Patent Pools – Legal and Economic Issues
- USPTO, Patent Pools: A Solution to the Problem of Access in Biotechnology Patents? (2000)
- Stanley P Kowalski, Intellectual Property Management Strategies to Accelerate the Development and Access of Vaccines and Diagnostics: Case Studies on Pandemic Influenza, Malaria and SARS. Pierce Law Faculty Scholarship Series. Paper 43 (2006).
- Robert P. Merges, Wilson Sonsini Goodrich & Rosati Professor of Law and Technology, Berkeley Law, Institutions for IP Transactions: The Case of Patent Pools, (1999)
- David W. Van Etten, Everyone in the Patent Pool: U.S. Philips Corp. v. International Trade Commission, 22 Berkeley Tech. L.J. 241 (2007)
- Steven C. Carlson, Patent Pools and the Antitrust Dilemma, 16 Yale J. on Reg. 359 (1999)
- Mark A. Lemley, Intellectual Property Rights and Standard-Setting Organizations. 90 Cal. L. Rev. 1889 (2002)
- David Serafino, Survey of Patent Pools Demonstrates Variety of Purposes and Management Structures, KEI Research Note 2007:6.
- Ebersole et al., Patent Pools and Standard Setting in Diagnostic Genetics. 23 Nat Biotechnol. 8 (2005).
- Carl Shapiro. Navigating the Patent Thicket: Cross Licenses, Patent Pools, and Standard Setting. Innovation Policy and the Economy. (2000).
- Ryan Lampe et al. Do Patent Pools Encourage Innovation? Evidence from the 19th-Century Sewing Machine Industry. SSRN. 2009
- Nathan Ford, et al. Rationing Antiretroviral Therapy in Africa – Treating Too Few, Too Late. 260 N Eng J Med 1808. (2009)
- United Kingdom’s All Party Parliamentary Group on AIDS report on HIV therapies, ‘A Treatment Timebomb’ (2009). The report sets out the scale of treatment need and discusses the patent pool as one of the potential new ways to lower drug prices and make new fixed dose combinations and pediatric formulations available.
- Response of UK International Development Minister Mike Foster. The Guardian
- Doctors Without Borders, Affordability, Availability and Adaptability of AIDS Drugs in Developing Countries: An On-going Challenge (2008)
- Doctors Without Borders, Running in Place: Too Many Patients Still in Urgent Need of HIV/AIDS Treatment (2008)
- UNITAID’s Medicines Patent Pool, Fact Sheet, Questions & Answers, WHO Briefing, International AIDS Conference Roundtable on UNITAID Medicines Pool (YouTube)
- UNITAID Briefing on the UNITAID HIV Medicines Patent Pool Initiative, June 2009
- Report, Agenda, Press Release, Preliminary Legal Review of Proposed Medicines Patent Pool (2007)
- Gilead statement on UNITAID Patent Pool: “[I]f structured appropriately, UNITAID patent pool can play a critical role in expanding access to antiretroviral treatment for patients around the world by encouraging the development of new fixed-dose combinations and pediatric formulations, lowering prices, while respecting intellectual property,” BBC Article, Aids Portal News, Gilead Statement to UNITAID
- Gilead’s Access to HIV programs, Leishmaniasis program, Access Principles
GlaxoSmithKline, Neglected Diseases, Patent Pools, and Universities
- GlaxoSmithKline CEO Andrew Witty’s February 2009 announcement at Harvard.
- GSK’s Neglected Disease Patent Pool. Overview, GSK’s Contribution, GSK’s Donated Patents, Collaborators, License Terms, FAQs.
- GSK announces royalty-free license for generic version of abacavir (Ziagen).
- GSK and Alnylam Pharmaceuticals announce more than 1500 issued or pending patent donations
- Mary Moran, et. al. Neglected Disease Research and Development: How Much Are We Really Spending? 6 PLOS Medicine 0137 (2009).
Partners & Supporters
- Boston University Center for Global Health & Development
- Drugs for Neglected Disease Initiative (DNDi)
- Doctors Without Borders
- Duke University’s Global Health Institute
- Emory University’s Office of Technology Transfer, Technology Transfer for Global Access Principles, Partnership with South African Drug Discovery Program
- Federal Trade Commission, Bureau of Competition, Office of Policy & Coordination
- Fenwick & West
- Fish & Richardson
- Gilead Sciences
- Institute for One World Health
- Knowledge Ecology International
- UC Berkeley Law (Boalt Hall)
- UC Berkeley Goldman School of Public Policy
- UC Berkeley Science, Technology, and Society Center
- UC Berkeley Henry Wheeler Center for Emerging and Neglected Diseases (CEND)
- UC Berkeley’s Office of IP & Industry Research Alliances (IPIRA)
- Via Licensing
- Wilson Sonsini Goodrich & Rosati